Tonix Pharmaceuticals (TNXP) Projected to Post Earnings on Tuesday

Tonix Pharmaceuticals (NASDAQ:TNXP) is expected to announce its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect Tonix Pharmaceuticals to post earnings of ($3.59) per share and revenue of $2.30 million for the quarter. Investors may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Friday, November 14, 2025 at 4:00 PM ET.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings results on Monday, August 11th. The company reported ($3.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.10) by ($0.76). The business had revenue of $2.00 million during the quarter, compared to analyst estimates of $2.60 million. Tonix Pharmaceuticals had a negative net margin of 828.22% and a negative return on equity of 57.93%. On average, analysts expect Tonix Pharmaceuticals to post $-1,763 EPS for the current fiscal year and $-542 EPS for the next fiscal year.

Tonix Pharmaceuticals Stock Down 2.4%

TNXP traded down $0.45 on Tuesday, reaching $18.30. The company’s stock had a trading volume of 214,940 shares, compared to its average volume of 1,303,806. The stock has a 50 day moving average of $24.13 and a two-hundred day moving average of $31.09. The company has a market capitalization of $160.42 million, a price-to-earnings ratio of -0.46 and a beta of 1.87. Tonix Pharmaceuticals has a fifty-two week low of $6.76 and a fifty-two week high of $130.00.

Institutional Investors Weigh In On Tonix Pharmaceuticals

Large investors have recently modified their holdings of the company. Royal Bank of Canada purchased a new stake in shares of Tonix Pharmaceuticals during the first quarter worth approximately $610,000. Geode Capital Management LLC raised its stake in shares of Tonix Pharmaceuticals by 182.4% during the second quarter. Geode Capital Management LLC now owns 175,212 shares of the company’s stock worth $6,305,000 after purchasing an additional 113,175 shares during the last quarter. JPMorgan Chase & Co. purchased a new stake in shares of Tonix Pharmaceuticals during the second quarter worth approximately $129,000. Legal & General Group Plc purchased a new stake in shares of Tonix Pharmaceuticals during the second quarter worth approximately $25,000. Finally, New York State Common Retirement Fund purchased a new stake in shares of Tonix Pharmaceuticals during the second quarter worth approximately $104,000. 82.26% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently issued reports on TNXP shares. Wall Street Zen downgraded Tonix Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, October 3rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Tonix Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $70.00.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.